A Comparative Study of the Clinical Effects of Targeted Treatments with Nilaparib and Olaparib on Recurrent Ovarian Cancer

Abstract

Objective: To study and compare the clinical effects of targeted treatments with Nilaparib and Olaparib on recurrent ovarian cancer. Methods: A total of 98 patients with recurrent ovarian cancer who were diagnosed and treated in our hospital from February 2019 to July 2021 were enrolled and randomly assigned to group A and group B, with 49 patients in each group. Patients in both groups received combined chemotherapy regimen of paclitaxel and cisplatin (TP). In addition, group A received Nilaparib while group B was treated with Olaparib. The two groups were compared with respect to clinical therapeutic effects and safety of medication. Results: The objective response rate (ORR) and disease control rate (DCR) were significantly higher in group A than in group B (p < 0.05). After treatment, the serum level of cancer antigen 125 (CA125) in group A was markedly lower than that in group B (p < 0.05). However, there were no significant differences in total incidence of adverse reactions between the two groups. Conclusions: Nilaparib produced a relatively better therapeutic effect in the treatment of recurrent ovarian cancer, when compared with Olaparib, and it decreased serum level of CA125. Therefore, the overall clinical effect of targeted treatment with Niraparib on recurrent ovarian cancer was better than that of Olaparib.